New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 10, 2012
18:08 EDTARIAARIAD announces long-term molecular response data on Ponatinib
ARIAD Pharmaceuticals announced updated molecular response data from its Phase 1 and pivotal Phase 2 trials of ponatinib, its investigational BCR-ABL inhibitor, in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia. The studies now show that 51% of chronic-phase CML patients in the Phase 1 trial achieved a major molecular response with a median follow-up of 30 months, and 34% of chronic-phase patients achieved MMR in the PACE trial with a median follow-up of 15 months.
News For ARIA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 22, 2015
07:37 EDTARIAARIAD announces data presentations at EHA Congress
Subscribe for More Information
May 20, 2015
10:29 EDTARIAOptions with decreasing implied volatility
Options with decreasing implied volatility: ZIOP KING ARIA CTRP WTW VHC XON KERX VIPS JCP
May 19, 2015
11:59 EDTARIAOptions with decreasing implied volatilit
Subscribe for More Information
May 18, 2015
10:37 EDTARIAOptions with decreasing implied volatility
Options with decreasing implied volatility: NLNK ARWR CTRP ZIOP CLNE ARIA VHC AOL KING XON PEIX
May 14, 2015
08:04 EDTARIAARIAD to present data on Iclusig, brigatinib at ASCO meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use